Research programme: hepatitis B virus therapeutics - Benitec

Drug Profile

Research programme: hepatitis B virus therapeutics - Benitec

Alternative Names: BB-101; BB-102; BB-103; BB-HB-331; Hepbarna; Hepbarna™ programme

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Benitec Biopharma - Biomics Biotechnologies (JV)
  • Class Small interfering RNA
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 19 Apr 2017 Interim pharmacodynamics data from preclinical studies in Hepatitis B presented at The International Liver Congress 2017 (ILS-2017)
  • 07 Mar 2017 Benitec Biopharma announces intention to submit IND for either BB 103 or BB 101 to US FDA by the end of 2017 (Benitec BioPharma 20-F, October 2016)
  • 20 Dec 2016 Pharmacodynamics data from a preclinial studies in Hepatits-B released by Bentic Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top